Rafferty Asset Management
BCRX icon

Rafferty Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Rafferty Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.66M Sell
265,618
-88,642
-25% -$802K 0.01% 575
2026
Q1 		$3.37M Sell
354,260
-28,296
-7% -$220K 0.01% 496
2025
Q4 		$2.98M Buy
382,556
+13,234
+4% +$95.7K 0.01% 558
2025
Q3 		$2.8M Buy
369,322
+68,371
+23% +$569K 0.01% 562
2025
Q2 		$2.7M Buy
300,951
+47,626
+19% +$444K 0.01% 537
2025
Q1 		$1.9M Buy
253,325
+18,489
+8% +$149K 0.01% 592
2024
Q4 		$1.77M Sell
234,836
-136,198
-37% -$1.03M 0.01% 676
2024
Q3 		$2.82M Sell
371,034
-94,697
-20% -$720K 0.01% 552
2024
Q2 		$2.88M Sell
465,731
-1,104,051
-70% -$6.09M 0.01% 539
2024
Q1 		$7.97M Buy
1,569,782
+614,195
+64% +$3.45M 0.03% 347
2023
Q4 		$5.72M Buy
955,587
+147,699
+18% +$856K 0.02% 420
2023
Q3 		$5.72M Sell
807,888
-167,075
-17% -$1.2M 0.03% 361
2023
Q2 		$6.86M Buy
974,963
+154,442
+19% +$1.24M 0.04% 348
2023
Q1 		$6.84M Buy
820,521
+52,448
+7% +$505K 0.05% 299
2022
Q4 		$8.82M Buy
768,073
+252,845
+49% +$3.15M 0.07% 219
2022
Q3 		$6.49M Buy
515,228
+127,901
+33% +$1.65M 0.07% 251
2022
Q2 		$4.1M Buy
387,327
+55,614
+17% +$574K 0.04% 318
2022
Q1 		$5.39M Sell
331,713
-120,924
-27% -$1.94M 0.03% 373
2021
Q4 		$6.27M Buy
452,637
+247,639
+121% +$3.28M 0.03% 290
2021
Q3 		$2.95M Buy
204,998
+48,891
+31% +$771K 0.02% 486
2021
Q2 		$2.47M Sell
156,107
-107,477
-41% -$1.46M 0.02% 611
2021
Q1 		$2.68M Buy
263,584
+151,233
+135% +$1.56M 0.02% 550
2020
Q4 		$837K Sell
112,351
-413,951
-79% -$2.13M 0.01% 555
2020
Q3 		$1.81M Buy
526,302
+303,685
+136% +$1.3M 0.02% 449
2020
Q2 		$1.06M Buy
222,617
+205,417
+1,194% +$820K 0.01% 528
2020
Q1 		$34K Sell
17,200
-128,884
-88% -$355K ﹤0.01% 584
2019
Q4 		$504K Sell
146,084
-125,292
-46% -$315K 0.01% 687
2019
Q3 		$777K Sell
271,376
-109,118
-29% -$339K 0.01% 592
2019
Q2 		$1.44M Buy
380,494
+275,454
+262% +$1.66M 0.03% 496
2019
Q1 		$855K Buy
+105,040
New +$899K 0.01% 580

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Rafferty Asset Management's BCRX Position: Q2 2026 in Review

Rafferty Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 25% in Q2 2026, selling an estimated $802K and leaving 265,618 shares worth $2.66M. The position accounts for 0.01% of the portfolio, ranked #575.

Rafferty Asset Management first reported a position in BCRX in Q1 2019 and has held it in 30 quarters since. The position peaked at $8.82M in Q4 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Rafferty Asset Management held 265,618 shares of BioCryst Pharmaceuticals worth $2.66M as of Q2 2026.
  • Rafferty Asset Management sold 88,642 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $802K.
  • BioCryst Pharmaceuticals made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #575 holding.
  • Rafferty Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
  • Rafferty Asset Management's BioCryst Pharmaceuticals position peaked at $8.82M in Q4 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.